← ANALYST RATINGS · TIPRANKS
AnaptysBio (ANAB): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $80.00, the highest $95.00, the lowest $60.00. The average is +71.6% from the last price of $46.61.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $95.00 | Buy | +103.8% | Reiterated | 05.10.26on TipRanks 11:30 | +0.7%next day −3.2% · 5 days −6.8% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $70.00 → $60.00−14.3% | Buy | +28.7% | Assigned | 30.09.26on TipRanks 07:35 | 0.0%next day −3.4% · 5 days −11.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $58.00 | Hold | +24.4% | Reiterated | 23.09.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $55.00 → $58.00+5.5% | Hold | +24.4% | Reiterated | 23.09.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $55.00 → $57.00+3.6% | Hold | +22.3% | Reiterated | 23.09.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $55.00 → $54.00−1.8% | Hold | +15.9% | Reiterated | 23.09.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $59.00 → $60.00+1.7% | Buy | +28.7% | Upgrade | 23.09.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $58.00 → $59.00+1.7% | Hold | +26.6% | Reiterated | 23.09.26on TipRanks 10:05 | — | |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $90.00 → $81.00−10.0% | Buy | +73.8% | Reiterated | 23.09.26on TipRanks 09:50 | −5.1%next day +1.9% · 5 days −0.3% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $75.00 | Buy | +60.9% | Reiterated | 22.09.26on TipRanks Sep 23 05:05 | −1.8%next day −5.1% · 5 days −5.4% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $76.00 | Buy | +63.1% | Assigned | 22.09.26on TipRanks 08:50 | −1.8%next day −5.1% · 5 days −5.4% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $95.00 | Buy | +103.8% | Reiterated | 22.09.26on TipRanks 06:45 | −1.8%next day −5.1% · 5 days −5.4% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Assigned | 25.08.26on TipRanks Aug 24 18:30 | −0.4%next day −0.7% · 5 days −4.8% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $93.00 | Buy | +99.5% | Reiterated | 21.07.26on TipRanks Jul 23 21:18 | +6.1%next day −2.0% · 5 days −2.1% | |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $60.00 → $75.00+25.0% | Buy | +60.9% | Reiterated | 31.03.26on TipRanks 08:15 | −2.8%next day +1.5% · 5 days +14.2% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $36.00 → $50.00+38.9% | Hold | +7.3% | Reiterated | 09.03.26on TipRanks 07:30 | +6.9%next day +4.0% · 5 days +9.9% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $140 | Buy | +200.4% | Reiterated | 04.03.26on TipRanks 07:40 | +13.9%next day −4.8% · 5 days +8.1% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $81.00 | Buy | +73.8% | Reiterated | 16.12.25on TipRanks Dec 17 10:55 | −0.9%next day +2.6% · 5 days +9.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering AnaptysBio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $80.00 at a price of $50.26 (+59.2%); now: $80.00 at $46.61 (+71.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 3 | 5 | 6 | 5 |
| Buy | 22 | 14 | 14 | 7 | 11 | 6 |
| Hold | 1 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About AnaptysBio
- CEO: Daniel Faga
- Employees: 104
- 10770 Wateridge Circle, San Diego, CA, 92121, US
- www.anaptysbio.com
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Data from the stock’s TipRanks forecast page, read 28 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗